Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003830 · ClinicalTrials.gov registry record · Phase 3
Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,611
- Enrollment target
- 20
- Study locations
NCT00003830 is a Phase 3 study of Breast Cancer that has completed, run by NSABP Foundation. The registered enrollment target is 5,611 participants, above the 2,799-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT00003830, a Phase 3 study of Breast Cancer, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,611 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Removing the sentinel lymph nodes and examining them under a microscope may help plan more effective surgery for breast cancer. It is not yet known if surgery to remove the sentinel lymph nodes is more effective with or without removal of the lymph nodes in the armpit in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery to remove the sentinel lymph nodes with or without removal of lymph nodes in the armpit in treating women who have breast cancer.
Conditions Studied
Interventions
- PROCEDURE conventional surgery
- PROCEDURE Sentinel node resection followed by node examination
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- Loma Linda University Cancer Institute at Loma Linda University Medical Center - Loma Linda
- Sutter Breast Cancer Group - Sacramento
- Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego - San Diego
- Stanford Cancer Center at Stanford University Medical Center - Stanford
Florida
- Halifax Medical Center - Daytona Beach
- Baptist Regional Cancer Institute - Jacksonville - Jacksonville
- University of Miami Sylvester Cancer Center - Miami
- CCOP - Mount Sinai Medical Center - Miami Beach
- Sarasota Memorial Hospital - Sarasota
Illinois
- MBCCOP-Cook County Hospital - Chicago
- Creticos Cancer Center at Advocate Illinois Masonic Medical Center - Chicago
- CCOP - Illinois Oncology Research Association - Peoria
Indiana
- Methodist Cancer Center at Methodist Hospital - Indianapolis
- CCOP - Northern Indiana CR Consortium - South Bend
Alabama
- MBCCOP - Gulf Coast - Mobile
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Hartford Hospital - Hartford
District of Columbia
- MBCCOP - Howard University Cancer Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,611 participants |
| Start Date | 1999-05 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003830
The ClinicalTrials.gov registry entry for NCT00003830 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,611 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,799-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% higher). The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which conventional surgery is the first listed.
NCT00003830 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00003830 about?
NCT00003830 is a clinical study titled "Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer". RATIONALE: Removing the sentinel lymph nodes and examining them under a microscope may help plan more effective surgery for breast cancer. It is not yet known if surgery to remove the sentinel lymph nodes is more effective with or without removal of the lymph nodes in the armpit in treating breast c...
What is the current status of trial NCT00003830?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,611 participants. The study started on 1999-05. Estimated completion is 2014-02.
What conditions does trial NCT00003830 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00003830?
The interventions under investigation include: conventional surgery (PROCEDURE), Sentinel node resection followed by node examination (PROCEDURE).
Who is sponsoring clinical trial NCT00003830?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003830 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.